Ikarugamycin
(Synonyms: 斑鸠霉素) 目录号 : GC43892An antiprotozoan antibiotic
Cas No.:36531-78-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ikarugamycin is a macrocyclic antibiotic first isolated from Streptomyces sp. that demonstrates potent antiprotozoal activity.[1] It exhibits cytotoxic effects in cancer cell lines, inhibiting cell proliferation (IC50 = 221.3 nM in HL-60 cells) through genotoxicity and by inducing apoptosis and activation of caspases.[2] It also was shown to significantly inhibit oxidized low-density lipoprotein-induced accumulation of cholesteryl esters in macrophages at 1-4 μM.[3] Additionally, ikarugamycin is used to inhibit clathrin-coated pit-mediated endocytosis.[4]
Reference:
[1]. Jomon, K., Kuroda, Y., Ajisaka, M., et al. A new antibiotic, ikarugamycin. J.Antibiot.(Tokyo) 25(5), 271-280 (1972).
[2]. Popescu, R., Heiss, E.H., Ferk, F., et al. Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cells. Mutation Research 709-710, 60-66 (2011).
[3]. Hasumi, K., Shinohara, C., Naganuma, S., et al. Inhibition of the uptake of oxidized low-density lipoprotein in macrophage J774 by the antibiotic ikarugamycin. European Journal of Biochemistry 205(2), 841-846 (1992).
[4]. Luo, T., Fredericksen, B.L., Hasumi, K., et al. Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. Journal of Virology 75(5), 2488-2492 (2001).
| Cas No. | 36531-78-9 | SDF | |
| 别名 | 斑鸠霉素 | ||
| 化学名 | (2R,3R,7Z,14S,19E)-3-ethyl-2,3,3aS,5aR,5bS,6,10,11,12,13,14,15,20aS,21,21aR,21bR-hexadecahydro-22-hydroxy-2-methyl-14,17-metheno-17H-as-indaceno[3,2-k][1,6]diazacycloheptadecine-9,16,18(1H)-trione | ||
| Canonical SMILES | O=C(C1=C(O)[C@H](CCCN2)NC1=O)/C=C/[C@@H]3C[C@@]4([H])[C@@](C=C[C@]5([H])[C@]4([H])C[C@@H](C)[C@H]5CC)([H])[C@H]3C/C=C\C2=O | ||
| 分子式 | C29H38N2O4 | 分子量 | 478.6 |
| 溶解度 | Soluble in DMSO，DMF, slightly in ethanol, methanol | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0894 mL | 10.4471 mL | 20.8943 mL |
| 5 mM | 0.4179 mL | 2.0894 mL | 4.1789 mL |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0894 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet